Trial Profile

Phase 1a clinical trial assessing SDC-1801 in healthy subjects

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 02 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SDC 1801 (Primary)
Indications Autoimmune disorders; COVID 2019 infections; COVID-19 pneumonia; Inflammatory bowel diseases; Multiple sclerosis; Psoriasis; Rheumatoid arthritis
Focus Adverse reactions
Sponsors Sareum

Most Recent Events

02 Aug 2022 New trial record
28 Jul 2022 According to Sareum Holdings media release, subject to regulatory approval from MHRA, this Phase 1a trial is planned to commence in Q4 2022
28 Jul 2022 According to Sareum Holdings media release, a Clinical Trial Authorisation application has been submitted to the UK Medicines and Healthcare Products Regulatory Agency for this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com